These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 27274551

  • 21. Utility of epithelial membrane antigen immunostaining in the differentiation between palmoplantar pustulosis and pompholyx.
    Yoon SY, Park HS, Yoon HS, Chung JH, Cho S.
    J Eur Acad Dermatol Venereol; 2013 Aug; 27(8):1054-6. PubMed ID: 22988903
    [No Abstract] [Full Text] [Related]

  • 22. Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary.
    Waks JW, Zimetbaum PJ.
    Expert Rev Cardiovasc Ther; 2013 Nov; 11(11):1461-71. PubMed ID: 24147516
    [Abstract] [Full Text] [Related]

  • 23. Dabigatran-induced chronic progressive immune hemolytic anemia: A case report.
    Gong JH, Liu GJ, Zhou F, Sun ZQ.
    J Stroke Cerebrovasc Dis; 2020 Aug; 29(8):104924. PubMed ID: 32689602
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Idarucizumab for Reversal of Dabigatran Prior to Acute Surgery: A Schematic Approach Based on a Case Report.
    Rosenberg L, Gerstrøm G, Nybo M.
    Basic Clin Pharmacol Toxicol; 2017 Apr; 120(4):407-410. PubMed ID: 27797449
    [Abstract] [Full Text] [Related]

  • 27. Dabigatran for the prevention and treatment of thromboembolic disorders.
    Enriquez A, Baranchuk A, Redfearn D, Simpson C, Abdollah H, Michael K.
    Expert Rev Cardiovasc Ther; 2015 May; 13(5):529-40. PubMed ID: 25843430
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Dabigatran in clinical practice.
    Nagarakanti R, Ellis CR.
    Clin Ther; 2012 Oct; 34(10):2051-60. PubMed ID: 23031622
    [Abstract] [Full Text] [Related]

  • 30. Spontaneous hemothorax due to dabigatran use in a patient with atrial fibrillation.
    Akgedik R, Günaydin Z, Bektas O, Karagöz A, Öztürk H.
    Clin Respir J; 2017 May; 11(3):394-396. PubMed ID: 26083004
    [No Abstract] [Full Text] [Related]

  • 31. Risk of major bleeding and the standard doses of dabigatran.
    Antoniazzi S, Berdaï D, Conti V, Clementi E, Salvo F.
    Eur J Intern Med; 2014 Jul; 25(6):e73-5. PubMed ID: 24629895
    [No Abstract] [Full Text] [Related]

  • 32. Left subconjunctival hemorrhage · renal dysfunction · international normalized ratio of 4.5 · Dx?
    Lehman N, Bryant G, Bender J, Koenigsfeld C, Logemann C, Sayler M.
    J Fam Pract; 2015 Oct; 64(10):E3-4. PubMed ID: 26551480
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation.
    Eikelboom JW, Connolly SJ, Hart RG, Wallentin L, Reilly P, Oldgren J, Yang S, Yusuf S.
    J Am Coll Cardiol; 2013 Sep 03; 62(10):900-8. PubMed ID: 23770182
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.